 SAN DIEGO, Jan. 12, 2021 GLOBE NEWSWIRE -- Travere Therapeutics, Inc. NASDAQ: TVTX today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease ESKD. Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis FSGS in pivotal Phase 3 clinical trials that are expected to report topline data from interim proteinuria assessments in 2021. 